GSK Statistics
Total Valuation
GSK has a market cap or net worth of $92.79 billion. The enterprise value is $112.27 billion.
| Market Cap | 92.79B |
| Enterprise Value | 112.27B |
Important Dates
The next confirmed earnings date is Wednesday, October 28, 2026, before market open.
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | Aug 14, 2026 |
Share Statistics
GSK has 4.01 billion shares outstanding. The number of shares has decreased by -1.36% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.01B |
| Shares Change (YoY) | -1.36% |
| Shares Change (QoQ) | -0.29% |
| Owned by Insiders (%) | 0.06% |
| Owned by Institutions (%) | 84.66% |
| Float | 3.88B |
Valuation Ratios
The trailing PE ratio is 14.51 and the forward PE ratio is 9.42.
| PE Ratio | 14.51 |
| Forward PE | 9.42 |
| PS Ratio | 2.11 |
| Forward PS | 2.68 |
| PB Ratio | 4.07 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 10.16 |
| P/OCF Ratio | 8.41 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.82, with an EV/FCF ratio of 12.29.
| EV / Earnings | 17.55 |
| EV / Sales | 2.55 |
| EV / EBITDA | 7.82 |
| EV / EBIT | 8.74 |
| EV / FCF | 12.29 |
Financial Position
The company has a current ratio of 0.82, with a Debt / Equity ratio of 1.06.
| Current Ratio | 0.82 |
| Quick Ratio | 0.52 |
| Debt / Equity | 1.06 |
| Debt / EBITDA | 1.66 |
| Debt / FCF | 2.66 |
| Interest Coverage | 14.65 |
Financial Efficiency
Return on equity (ROE) is 33.38% and return on invested capital (ROIC) is 26.38%.
| Return on Equity (ROE) | 33.38% |
| Return on Assets (ROA) | 10.01% |
| Return on Invested Capital (ROIC) | 26.38% |
| Return on Capital Employed (ROCE) | 24.09% |
| Weighted Average Cost of Capital (WACC) | 5.26% |
| Revenue Per Employee | $659,077 |
| Profits Per Employee | $95,696 |
| Employee Count | 66,841 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 1.42 |
Taxes
In the past 12 months, GSK has paid $850.47 million in taxes.
| Income Tax | 850.47M |
| Effective Tax Rate | 10.86% |
Stock Price Statistics
The stock price has increased by +7.27% in the last 52 weeks. The beta is 0.28, so GSK's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | +7.27% |
| 50-Day Moving Average | 50.04 |
| 200-Day Moving Average | 52.37 |
| Relative Strength Index (RSI) | 33.52 |
| Average Volume (20 Days) | 4,482,781 |
Short Selling Information
The latest short interest is 14.65 million, so 0.73% of the outstanding shares have been sold short.
| Short Interest | 14.65M |
| Short Previous Month | 14.78M |
| Short % of Shares Out | 0.73% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.33 |
Income Statement
In the last 12 months, GSK had revenue of $44.05 billion and earned $6.40 billion in profits. Earnings per share was $3.13.
| Revenue | 44.05B |
| Gross Profit | 32.38B |
| Operating Income | 12.85B |
| Pretax Income | 7.83B |
| Net Income | 6.40B |
| EBITDA | 14.35B |
| EBIT | 12.85B |
| Earnings Per Share (EPS) | $3.13 |
Balance Sheet
The company has $4.12 billion in cash and $24.27 billion in debt, with a net cash position of -$20.15 billion or -$5.03 per share.
| Cash & Cash Equivalents | 4.12B |
| Total Debt | 24.27B |
| Net Cash | -20.15B |
| Net Cash Per Share | -$5.03 |
| Equity (Book Value) | 22.79B |
| Book Value Per Share | 5.84 |
| Working Capital | -5.27B |
Cash Flow
In the last 12 months, operating cash flow was $11.03 billion and capital expenditures -$1.90 billion, giving a free cash flow of $9.13 billion.
| Operating Cash Flow | 11.03B |
| Capital Expenditures | -1.90B |
| Depreciation & Amortization | 1.50B |
| Net Borrowing | 1.03B |
| Free Cash Flow | 9.13B |
| FCF Per Share | $2.28 |
Margins
Gross margin is 73.49%, with operating and profit margins of 29.17% and 14.52%.
| Gross Margin | 73.49% |
| Operating Margin | 29.17% |
| Pretax Margin | 17.78% |
| Profit Margin | 14.52% |
| EBITDA Margin | 32.58% |
| EBIT Margin | 29.17% |
| FCF Margin | 20.78% |
Dividends & Yields
This stock pays an annual dividend of $1.79, which amounts to a dividend yield of 3.84%.
| Dividend Per Share | $1.79 |
| Dividend Yield | 3.84% |
| Dividend Growth (YoY) | 10.29% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 57.11% |
| FCF Payout Ratio | 78.44% |
| Buyback Yield | 1.36% |
| Shareholder Yield | 5.20% |
| Earnings Yield | 6.89% |
| FCF Yield | 9.84% |
Analyst Forecast
The average price target for GSK is $60.51, which is 30.13% higher than the current price. The consensus rating is "Buy".
| Price Target | $60.51 |
| Price Target Difference | 30.13% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 3.87% |
| EPS Growth Forecast (3Y) | 5.01% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 19, 2022. It was a reverse split with a ratio of 1:1.25.
| Last Split Date | Jul 19, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:1.25 |
Scores
GSK has an Altman Z-Score of 2.2 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.2 |
| Piotroski F-Score | 7 |